News

Harrow Inc. Expands Portfolio with Melt Pharmaceuticals Deal

Harrow Inc. Expands Portfolio with Melt Pharmaceuticals Deal

Harrow Inc. Makes Strategic Move to Acquire Melt Pharmaceuticals

Harrow, a prominent provider of ophthalmic disease management solutions in North America, has recently announced its agreement to acquire Melt Pharmaceuticals, Inc., a pioneering clinical-stage pharmaceutical company known for its innovative non-opioid, non-IV therapies for procedural sedation. This transaction is a significant step forward for Harrow and aligns with its mission to enhance patient care and address the long-standing issues associated with opioid use in medical settings.

Revolutionizing Patient Sedation with MELT-300

Melt's flagship product, MELT-300, is an exciting new therapy designed to provide effective sedation without requiring intravenous administration. This product combines a fixed-dose formulation of midazolam (3mg) and ketamine (50mg) delivered sublingually, allowing for quicker and more predictable sedation outcomes in various medical procedures. Such advancements are particularly vital in an era where the medical community seeks alternatives to opioids, addressing both patient safety and comfort effectively.

The Benefits of MELT-300

Proven Results

The pivotal LOUISE Phase 3 Study showcased impressive results, with MELT-300 demonstrating superiority over both sublingual midazolam alone and placebo in achieving successful procedural sedation. Notably, the study revealed a significant reduction in the need for rescue sedation, highlighting the therapy's potential advantages over traditional sedation methods.

Future Regulatory Submission Plans

Harrow intends to submit a New Drug Application (NDA) to the FDA for MELT-300 with the aim of commercial launch in the coming years. This proactive approach illustrates Harrow's commitment to bringing this innovative solution to market and redefining sedation practices.

Strategic Advantages for Harrow

Harrow's acquisition of Melt Pharmaceuticals is more than just a business move; it's a strategic decision that unlocks several important advantages:

Market Expansion

The entry into the multi-billion-dollar U.S. procedural sedation market presents a substantial opportunity for growth. MELT-300 has the potential to not only replace but also complement IV sedation across various medical interventions.

Enhancing Patient Experience

MELT-300 facilitates a more patient-friendly experience with its under-the-tongue delivery method, minimizing the discomfort and anxiety typically associated with sedatives. This innovation is expected to simplify care and improve comfort during procedures.

Global Reach

With patents secured in key regions around the world, including North America and Europe, Harrow aims to partner with international entities to extend MELT-300's availability and benefit patients globally. Such initiatives underline the company's long-term vision and commitment to addressing global health challenges.

Leadership Insights

Mark L. Baum, the CEO of Harrow, expressed excitement over the acquisition, emphasizing its role in expanding Harrow's portfolio of advanced treatment options. He believes that MELT-300 will not only enhance patient outcomes but also significantly broaden the market opportunities available to the company.

Similarly, Dr. Larry Dillaha, CEO of Melt Pharmaceuticals, highlighted the groundbreaking nature of MELT-300, asserting that FDA approval would mark a paradigm shift in sedation protocols, benefiting patients in the U.S. and beyond.

About Harrow

Harrow Inc. (NASDAQ: HROW) is dedicated to improving the lives of patients through innovative ophthalmic disease management solutions. With a robust portfolio addressing various ocular conditions, the company is committed to delivering effective and affordable therapies that enhance clinical outcomes.

About Melt Pharmaceuticals

Melt Pharmaceuticals, Inc. focuses on developing unique non-IV, non-opioid sedation and analgesic treatments. Aimed at improving procedural sedation, their approach reflects a commitment to innovation and patient-centered care.

Frequently Asked Questions

What is Harrow acquiring from Melt Pharmaceuticals?

Harrow is acquiring Melt Pharmaceuticals to gain access to innovative non-opioid sedation therapies, including the lead product MELT-300.

How does MELT-300 work?

MELT-300 is a sublingual formulation combining midazolam and ketamine, providing rapid sedation without intravenous delivery.

When is the expected FDA submission for MELT-300?

Harrow plans to submit a New Drug Application for MELT-300 to the FDA, aiming for a launch around 2028.

What are the potential market applications for MELT-300?

MELT-300 can be used in various medical procedures, including ophthalmic surgeries, dental procedures, and more, potentially revolutionizing sedation in these settings.

How will this acquisition impact Harrow's business strategy?

This acquisition allows Harrow to diversify its product offerings, expand into new markets, and improve patient experiences within its current surgical portfolio.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Weight Loss Solutions: ASC36 and ASC35 Development

Updated Category News Views 312

Exciting Co-formulation Advancements by Ascletis Pharma Ascletis Pharma Inc. has made a significant stride in obesity treatment with the co-formulation of ASC36, a monthly amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. These innovative therapies aim to offer better patient outcomes through advanced pharmacokinetic profiles and a robust efficacy in weight...

Continue Reading
Schouw & Co. Reports Steady Q1 Performance Amidst Challenges

Updated Category News Views 291

Overview of Q1 2025 Performance Recently, Schouw & Co. disclosed their interim report for the first quarter of 2025, highlighting a performance that generally met expectations despite ongoing economic turbulence. While the disturbances in the market have generated caution among customers, the direct effects on Schouw & Co.'s operations seem to have been minimal. Key...

Continue Reading
Parker Hannifin to Present at Jefferies Industrials Conference

Updated Category News Views 153

Parker Hannifin Set to Present at the Jefferies Industrials Conference Parker Hannifin Corporation (NYSE: PH), a recognized leader in motion and control technologies worldwide, has announced its participation in the prestigious Jefferies Industrials Conference. This important event will take place in early September, bringing together industry leaders and innovators to...

Continue Reading
374Water Innovatively Enhances Waste Management Solutions

Updated Category News Views 121

Revolutionizing Waste Management with AirSCWO Technology DURHAM, N.C. – 374Water Inc. (NASDAQ: SCWO) is making significant advancements with its innovative AirSCWO technology aimed at revolutionizing waste management practices. The Company has partnered with the Orange County Sanitation District (OC San) to implement its cutting-edge AirSCWO 6 System at their treatment...

Continue Reading
SharpLink Gaming Expands Footprint in Crypto Gaming Market

Updated Category News Views 548

SharpLink Gaming Advances in Crypto Gaming with Strategic Investment SharpLink Gaming, Inc. (NASDAQ: SBET), a notable player in online marketing for sports betting and iGaming, has declared an exciting venture that marks its entry into the rapidly growing crypto gaming sector. Recently, the company secured a 10% equity stake in Armchair Enterprises, the parent company of...

Continue Reading